Accuracy of leukocyte alkaline phosphatase score to predict JAK2 V617F mutation

Haematologica

Volumn 92, Issue 5, 2007, Pages 704-705

  Basquiera, Ana L ^a   Fassetta, Fernanda ^a   Soria, Néstor ^b   Barral, José Moreno ^b   Ricchi, Brenda ^a   García, Juan J ^a  

^a HOSPITAL PRIVADO   (Argentina)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

JAK2; LAP; Myeloproliferative disorders; Sensitivity; Specificity

Indexed keywords

ALKALINE PHOSPHATASE; ENZYME; JANUS KINASE 2; JAK2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE LEUKOCYTE LEVEL; ARTICLE; BLOOD SMEAR; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GRANULOCYTE; HUMAN; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PREDICTION; WORLD HEALTH ORGANIZATION; ADULT; AGED; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; BLOOD; ENZYMOLOGY; FEMALE; GENETICS; LETTER; LEUKOCYTE; LEUKOCYTE ACTIVATION; MALE; MIDDLE AGED; MISSENSE MUTATION; POINT MUTATION; PREDICTION AND FORECASTING; SINGLE BLIND PROCEDURE; VALIDATION STUDY;

ADULT; AGED; ALKALINE PHOSPHATASE; AMINO ACID SUBSTITUTION; AREA UNDER CURVE; FEMALE; HUMANS; JANUS KINASE 2; LEUKOCYTES; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; NEUTROPHIL ACTIVATION; POINT MUTATION; PREDICTIVE VALUE OF TESTS; SINGLE-BLIND METHOD;

EID: 34447319444     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10991     Document Type: Article

References (10)

1. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-6.
2. Kaplow LS. A Histochemical procedure for localizing and evaluating leukocyte alkaline phosphatase activity in smears of blood and marrow. Blood 1955;10:1023-9.
3. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339-51.
4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutations of the tyrosine kinase JAK2 in human myeloproliferative disorders. Cancer Genome Project. Lancet 2005;365:1054-61.
5. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005;434:1144-8.
6. + cells into peripheral blood in myeloproliferative disorders. Blood 2006;107:3676-82.
7. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study. United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group. Lancet 2005;366:1945-53.
8. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
9. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thromocythemia. Blood 2006;108:2435-7.
10. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006;108:1865-7.